Mechanochemistry towards greener pharmaceuticals
Innovative processes to revolutionise how we manufacture drugs and chemicals
Greener pharma
The pharmaceutical industry generates tons of toxic waste and carbon emissions. Moreover, it often relies on the supply chains of chemicals and catalysts, which limits timely production during emergencies.
Mechano…what?
Mechanochemistry gets rid of solvents. It uses mechanical force, like grinding and milling, to drive chemical reactions. It’s succesfully used by other industrial sectors (aerospace, cosmetics, fertilisers…). Now, IMPACTIVE will validate its use in pharma.
An impactful solution
IMPACTIVE is a project funded by the European Commission, which counts on 17 partners in 10 different countries. Our expertise covers the whole value chain, from research to industry and innovation, which will ensure our solutions find ways to market.
Strong industrial collaboration
IMPACTIVE counts with the industry from the start. 2 international companies (Merck & Novartis) are part of the project, to help with the scaling up.
News
+ Go to news page
IMPACTIVE turns the final page with great success
The IMPACTIVE team just came back from our final general assembly in Montpellier, France, last week. Four years of work condensed into two intense days, that bring our project to a close.
Exploring dynamics in our upcoming webinar
Why does a mechanochemical reaction that works perfectly in your mill behave differently in someone else’s? In our tenth and final webinar, Maria Carta will explain how jar geometry and milling conditions shape what happens inside the reactor — and introduces Athanor, the free simulation tool developed within IMPACTIVE. All on Wednesday, 23 September at 16:00 CEST.
Green by design: a policy roadmap for Europe’s pharmaceutical future
Medicines keep Europe healthy. However, making them, using them and disposing of them takes a toll on the environment. We’ve joined forces within Green Pharma Cluster to set out what the EU can do about it, in a new policy brief: Towards a Green Pharmaceutical Future in Europe.